Sun's Halol Site Faces FDA Action
But Dent In Indian Firm's Business May Be Limited
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
